Related Experiment Video

Updated: Aug 8, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever

S Ali1, A M Vollaard, S Widjaja

  • 1Department of Infectious Diseases, Leiden University Medical Centre, the Netherlands.

Clinical and Experimental Immunology
|June 1, 2006
PubMed

Insights

Genetic variations in the PARK2/PACRG gene cluster may influence susceptibility to infectious diseases. A specific polymorphism, PARK2_e01(-2599) allele T, is linked to increased risk of typhoid and paratyphoid fever.

Area of Science:

  • Genetics
  • Immunology
  • Infectious Diseases

Background:

  • Host genetic factors play a role in infectious disease susceptibility and outcomes.
  • Polymorphisms in the PARK2/PACRG gene cluster, involved in protein degradation, have been linked to leprosy.
  • Salmonella typhi and Salmonella paratyphi A are intracellular pathogens that elicit immune responses similar to mycobacteria.

Purpose of the Study:

  • To investigate the association between PARK2/PACRG gene polymorphisms and susceptibility to Salmonella typhi and Salmonella paratyphi A infections.
  • To determine if genetic variations in PARK2/PACRG influence the risk of developing typhoid and paratyphoid fever.

Main Methods:

  • A case-control study was conducted in Jakarta, Indonesia.
  • Polymorphisms PARK_e01(-697), PARK2_e01(-2599), rs1333955, and rs1040079 were analyzed using polymerase chain reaction and restriction fragment length polymorphism.
  • Samples were collected from patients with confirmed typhoid fever (n=90), paratyphoid fever (n=26), fever controls (n=337), and community controls (n=322).

Main Results:

  • The PARK2_e01(-2599) allele T showed a significant association with typhoid and paratyphoid fever (Odds Ratio: 1.51, 95% Confidence Interval: 1.02-2.23).
  • No significant association was found for polymorphisms PARK_e01(-697), rs1333955, and rs1040079.
  • The association of PARK2_e01(-2599) T with typhoid fever was less pronounced compared to its association with leprosy.

Conclusions:

  • The PARK2_e01(-2599) polymorphism in the PARK2/PACRG gene cluster plays a minor but significant role in susceptibility to Salmonella typhi and Salmonella paratyphi A.
  • These findings contribute to understanding the genetic basis of host susceptibility to enteric bacterial infections.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...